Related Experiment Video
Updated: Jan 19, 2026
10:44
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
10.3K
PharmVar GeneFocus: CYP2D6
Charity Nofziger1, Amy J Turner2,3, Katrin Sangkuhl4
1PharmGenetix GmbH, Niederalm, Austria.
Clinical Pharmacology and Therapeutics
|September 24, 2019
Summary
The Pharmacogene Variation Consortium (PharmVar) standardizes naming for the CYP2D6 gene. This ensures accurate understanding of genetic variations impacting drug response and guides pharmacogenomics resources like PharmGKB and CPIC.
Area of Science:
- Pharmacogenomics
- Human Genetics
- Drug Metabolism
Background:
- The CYP2D6 gene locus is highly polymorphic.
- Genetic variations in CYP2D6 significantly affect drug metabolism, influencing efficacy and safety.
- Standardized nomenclature is crucial for interpreting CYP2D6 genetic data.
Purpose of the Study:
- To provide a comprehensive overview of CYP2D6 genetic variation.
- To explain the nomenclature system provided by the Pharmacogene Variation Consortium (PharmVar).
- To describe the utilization of PharmVar data by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC).
Main Methods:
- Literature review and data synthesis.
- Description of the PharmVar nomenclature for CYP2D6 alleles.
- Explanation of how PharmGKB and CPIC integrate PharmVar data.
Main Results:
- PharmVar offers a standardized nomenclature for CYP2D6 genetic variations.
- This nomenclature facilitates consistent interpretation of CYP2D6 genotype-phenotype relationships.
- PharmGKB and CPIC leverage PharmVar data for clinical decision support.
Conclusions:
- Standardized CYP2D6 nomenclature is essential for pharmacogenomics.
- PharmVar's system enhances the utility of pharmacogenomic information.
- Accurate CYP2D6 variant interpretation improves drug efficacy and safety.
Related Concept Videos
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
169
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
169
01:26Pharmacokinetics: Drug–Food and Drug–Viral Interactions
221
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
221
01:21Factors Affecting Drug Response: Overview
3.0K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.0K
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
198
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
198
01:19Factors Affecting Drug Biotransformation: Biological
525
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
525
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
257
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
257